Toxic epidermal necrolysis: Review of pathogenesis and management

Journal of the American Academy of Dermatology

Volumn 66, Issue 6, 2012, Pages 995-1003

  Downey, Andrew ^a   Jackson, Chris ^b   Harun, Nadia ^c   Cooper, Alan ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

CTL; cytotoxic T lymphocyte; intravenous immunoglobulin; IVIg; natural killer (cell); NK; reactive oxygen species; ROS; SJS; Stevens Johnson syndrome; TEN; TNF; toxic epidermal necrolysis; tumor necrosis factor

Indexed keywords

CORTICOSTEROID; FAS LIGAND; GRANULYSIN; IMMUNOGLOBULIN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CELL DAMAGE; CLINICAL FEATURE; DISEASE CLASSIFICATION; ETHNICITY; GENETIC ASSOCIATION; HUMAN; KERATINOCYTE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TOXIC EPIDERMAL NECROLYSIS; WOUND CARE;

APOPTOSIS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PLASMAPHERESIS; PROGNOSIS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84861235187     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.09.029     Document Type: Review

References (84)

1. L.E. French Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding Allergol Int 55 2006 9 16
2. F.A. Pereira, A.V. Mudgil, and D.M. Rosmarin Toxic epidermal necrolysis J Am Acad Dermatol 56 2007 181 200
3. K. Wolff, L.A. Goldsmith, S.I. Katz, B.A. Gilchrest, A.S. Paller, and D.J. Lefell Fitzpatrick's Dermatology in general medicine 7th ed. 2007 McGraw Hill
4. B. Rzany, M. Mockenhaupt, U. Stocker, O. Hamouda, and E. Schopf Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany Arch Dermatol 129 1993 1059
5. J. Wu, C. Metz, X. Xu, R. Abe, A.W. Gibson, and J.C. Edberg A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients J Immunol 170 2003 132 138
6. A.M. Quinn, K. Brown, B.K. Bonish, J. Curry, K.B. Gordon, and J. Sinacore Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis Arch Dermatol 141 2005 683 687
7. P. Paquet, and G.E. Pierard Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis (review) Int J Mol Med 19 2007 3 10
8. J.C. Roujeau, and R.S. Stern Severe adverse cutaneous reactions to drugs N Engl J Med 331 1994 1272 1285
9. E. Letkko, B.S. Papaliodis, G.N. Papaliodis, Y.J. Daoud, A.R. Ahmed, and C.S. Foster Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature Ann Allergy Asthma Immunol 94 2005 419 436
10. S.D. Imahara, J.H. Holmes 4th, D.M. Heimbach, L.E. Engrav, S. Honari, and M.B. Klein SCORTEN overestimates mortality in the setting of a standardized treatment protocol J Burn Care Res 27 2006 270 275
11. Y. Mukasa, and N. Craven Management of toxic epidermal necrolysis and related syndromes Postgrad Med J 84 2008 60 65
12. S. Bastuji-Garin, N. Fouchard, M. Bertocchi, J.C. Roujeau, J. Revuz, and P. Wolkenstein SCORTEN: a severity-of-illness score for toxic epidermal necrolysis J Invest Dermatol 115 2000 149 153
13. M. Mockenhaupt, C. Viboud, A. Dunant, L. Naldi, S. Halevy, and J.N. Bouwes Bavinck Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study J Invest Dermatol 128 2008 35 44
14. D. Dobrosavljevic, M.V. Milinkovic, and M.M. Nikolic Toxic epidermal necrolysis following morbilli-parotitis vaccination J Eur Acad Dermatol Venereol 13 1999 59 61
15. D. Stevens, P.G. Swift, P.G. Johnston, P.J. Kearney, B.D. Corner, and D. Burman Mycoplasma pneumoniae infections in children Arch Dis Child 53 1978 38 42
16. W.H. Chung, S.I. Hung, H.S. Hong, M.S. Hsih, L.C. Yang, and H.C. Ho Medical genetics: a marker for Stevens-Johnson syndrome Nature 428 2004 486
17. S.I. Hung, W.H. Chung, L.B. Liou, C.C. Chu, M. Lin, and H.P. Huang HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Proc Natl Acad Sci U S A 102 2005 4134 4139
18. C. Locharernkul, J. Loplumlert, C. Limotai, W. Korkij, T. Desudchit, and S. Tongkobpetch Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B1502 allele in Thai population Epilepsia 49 2008 2087 2091
19. C.B. Man, P. Kwan, L. Baum, E. Yu, K.M. Lau, and A.S. Cheng Association between HLA-B1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese Epilepsia 48 2007 1015 1018
20. Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions - Carbamazepine. United States Food and Drug Administration. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm. Accessed November 16, 2011.
21. Y. Wu, J.P. Sanderson, J. Farrell, N.S. Drummond, A. Hanson, and E. Bowkett Activation of T cells by carbamazepine and carbamazepine metabolites J Allergy Clin Immunol 118 2006 233 241
22. N. Kaniwa, Y. Saito, M. Aihara, K. Matsunaga, M. Tohkin, and K. Kurose HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis Pharmacogenomics 9 2008 1617 1622
23. C. Lonjou, N. Borot, P. Sekula, N. Ledger, L. Thomas, and S. Halevy A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs Pharmacogenet Genomics 18 2008 99 107
24. W. Tassaneeyakul, T. Jantararoungtong, P. Chen, PY. Lin, S. Tiamkao, and U. Khunarkornsiri Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population Pharmacogenet Genomics 19 2009 704 709
25. R. Abe Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases J Dermatol Sci 52 2008 151 159
26. I. Viard, P. Wehrli, R. Bullani, P. Schneider, N. Holler, and D. Salomon Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin Science 282 1998 490 493
27. R. Abe, T. Shimizu, A. Shibaki, H. Nakamura, H. Watanabe, and H. Shimizu Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand Am J Pathol 162 2003 1515 1520
28. K. Stur, F.M. Karlhofer, and G. Stingl Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas J Invest Dermatol 127 2007 802 807
29. M. Tohyama, Y. Shirakata, K. Sayama, and K. Hashimoto The influence of hepatic damage on serum soluble Fas ligand levels of patients with drug rashes J Allergy Clin Immunol 123 2009 971 972 author reply 972
30. M. Tohyama, Y. Shirakata, K. Sayama, and K. Hashimoto A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome Br J Dermatol 159 2008 981 984
31. W.H. Chung, S.I. Hung, J.Y. Yang, S.C. Su, S.P. Huang, and C.Y. Wei Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis Nat Med 14 2008 1343 1350
32. A. Deng, S. Chen, Q. Li, S.C. Lyu, C. Clayberger, and A.M. Krensky Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator J Immunol 174 2005 5243 5248
33. P. Paquet, and G.E. Pierard New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited Drug Saf 33 2010 189 212
34. P. Paquet, and G.E. Pierard Glutathione-S-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes Skin Pharmacol Physiol 20 2007 66 70
35. J.D. Hayes, and D.J. Pulford The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance Crit Rev Biochem Mol Biol 30 1995 445 600
36. B. Hermes, N. Haas, and B.M. Henz [Plasmapheresis and immunopathogenetic aspects of toxic epidermal necrolysis] Hautarzt 47 1996 749 753 In German
37. P. Paquet, A. Nikkels, J.E. Arrese, A. Vanderkelen, and G.E. Pierard Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis Arch Dermatol 130 1994 605 608
38. S.J. Posadas, A. Padial, M.J. Torres, C. Mayorga, L. Leyva, and E. Sanchez Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity J Allergy Clin Immunol 109 2002 155 161
39. S.J. Posadas, M.J. Torres, C. Mayorga, C. Juarez, and M. Blanca Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs Blood Cells Mol Dis 29 2002 179 189
40. R. Arnold, M. Seifert, K. Asadullah, and H.D. Volk Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines J Immunol 162 1999 7140 7147
41. T.A. Chave, N.J. Mortimer, M.J. Sladden, A.P. Hall, and P.E. Hutchinson Toxic epidermal necrolysis: current evidence, practical management and future directions Br J Dermatol 153 2005 241 253
42. S. Moncada, R.M. Palmer, and E.A. Higgs Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacol Rev 43 1991 109 142
43. K.D. Kroncke, K. Fehsel, and V. Kolb-Bachofen Nitric oxide: cytotoxicity versus cytoprotection - how, why, when, and where? Nitric Oxide 1 1997 107 120
44. E. Morel, S. Escamochero, R. Cabanas, R. Diaz, A. Fiandor, and T. Bellon CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis J Allergy Clin Immunol 125 2010 703 710 710 e1-710 e8
45. A. Nassif, A. Bensussan, L. Boumsell, A. Deniaud, H. Moslehi, and P. Wolkenstein Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells J Allergy Clin Immunol 114 2004 1209 1215
46. Y. Mizukawa, Y. Yamazaki, and T. Shiohara In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption Br J Dermatol 158 2008 1230 1238
47. R. Takahashi, Y. Kano, Y. Yamazaki, M. Kimishima, Y. Mizukawa, and T. Shiohara Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome J Immunol 182 2009 8071 8079
48. T. Bellon, L. Alvarez, C. Mayorga, E. Morel, M.J. Torres, and M.A. Martin-Diaz Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases Br J Dermatol 162 2010 1014 1022
49. E. de Araujo, V. Dessirier, G. Lapree, L. Valeyrie-Allanore, N. Ortonne, and E.N. Stathopoulos Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis Exp Dermatol 20 2011 107 112
50. L. Verneuil, P. Ratajczak, C. Allabert, C. Leboeuf, F. Comoz, and A. Janin Endothelial cell apoptosis in severe drug-induced bullous eruptions Br J Dermatol 161 2009 1371 1375
51. I. Garcia-Doval, L. LeCleach, H. Bocquet, X.L. Otero, and J.C. Roujeau Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136 2000 323 327
52. T. McGee, and A. Munster Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center Plast Reconstr Surg 102 1998 1018 1022
53. T.L. Palmieri, D.G. Greenhalgh, J.R. Saffle, R.J. Spence, M.D. Peck, and J.C. Jeng A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century J Burn Care Rehabil 23 2002 87 96
54. F.W. Endorf, L.C. Cancio, and N.S. Gibran Toxic epidermal necrolysis clinical guidelines J Burn Care Res 29 2008 706 712
55. P. Boorboor, P.M. Vogt, F.G. Bechara, Q. Alkandari, M. Aust, and A. Gohritz Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients Burns 34 2008 487 492
56. A.H. Dorafshar, S.R. Dickie, A.B. Cohn, J.K. Aycock, A. O'Connor, and A. Tung Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach Plast Reconstr Surg 122 2008 154 160
57. S.H. Huang, S.H. Wu, I.F. Sun, S.S. Lee, C.S. Lai, and S.D. Lin AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN) Burns 34 2008 63 66
58. J. Revuz, D. Penso, J.C. Roujeau, J.C. Guillaume, C.R. Payne, and J. Wechsler Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients Arch Dermatol 123 1987 1160 1165
59. P.H. Halebian, V.J. Corder, M.R. Madden, J.L. Finklestein, and G.T. Shires Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids Ann Surg 204 1986 503 512
60. D.M. Heimbach, L.H. Engrav, J.A. Marvin, T.J. Harnar, and B.J. Grube Toxic epidermal necrolysis. A step forward in treatment JAMA 257 1987 2171 2175
61. J. Schneck, J.P. Fagot, P. Sekula, B. Sassolas, J.C. Roujeau, and M. Mockenhaupt Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study J Am Acad Dermatol 58 2008 33 40
62. D.N. Herndon Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids J Am Coll Surg 180 1995 340 342
63. N. Al-Mutairi, J. Arun, N.E. Osama, Z. Amr, A.S. Mazen, and A. Ibtesam el Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis Int J Dermatol 43 2004 847 851
64. E. Campione, G.C. Marulli, A.M. Carrozzo, M.S. Chimenti, A. Costanzo, and L. Bianchi High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis Acta Derm Venereol 83 2003 430 432
65. C. Prins, C. Vittorio, R.S. Padilla, T. Hunziker, P. Itin, and J. Forster Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study Dermatology 207 2003 96 99
66. R. Shortt, M. Gomez, N. Mittman, and R. Cartotto Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis J Burn Care Rehabil 25 2004 246 255
67. M. Stella, P. Cassano, D. Bollero, A. Clemente, and G. Giorio Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience Dermatology 203 2001 45 49
68. J.T. Trent, R.S. Kirsner, P. Romanelli, and F.A. Kerdel Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience Arch Dermatol 139 2003 39 43
69. P. Tristani-Firouzi, M.J. Petersen, J.R. Saffle, S.E. Morris, and J.J. Zone Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children J Am Acad Dermatol 47 2002 548 552
70. K.M. Brown, G.M. Silver, M. Halerz, P. Walaszek, A. Sandroni, and R.L. Gamelli Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 25 2004 81 88
71. N. Bachot, J. Revuz, and J.C. Roujeau Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression Arch Dermatol 139 2003 33 36
72. L.E. French, J.T. Trent, and F.A. Kerdel Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding Int Immunopharmacol 6 2006 543 549
73. J. Trent, M. Halem, L.E. French, and F. Kerdel Toxic epidermal necrolysis and intravenous immunoglobulin: a review Semin Cutan Med Surg 25 2006 91 93
74. G. Bamichas, T. Natse, F. Christidou, M. Stangou, A. Karagianni, and S. Koukourikos Plasma exchange in patients with toxic epidermal necrolysis Ther Apher 6 2002 225 228
75. G.C. Chaidemenos, F. Chrysomallis, K. Sombolos, O. Mourellou, D. Ioannides, and M. Papakonstantinou Plasmapheresis in toxic epidermal necrolysis Int J Dermatol 36 1997 218 221
76. C.A. Egan, W.J. Grant, S.E. Morris, J.R. Saffle, and J.J. Zone Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis J Am Acad Dermatol 40 1999 458 461
77. D. Kamanabroo, W. Schmitz-Landgraf, and B.M. Czarnetzki Plasmapheresis in severe drug-induced toxic epidermal necrolysis Arch Dermatol 121 1985 1548 1549
78. G. Sakellariou, P. Koukoudis, J. Karpouzas, E. Alexopoulos, D. Papadopoulou, and F. Chrisomalis Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN) Int J Artif Organs 14 1991 634 638
79. J.M. Arevalo, J.A. Lorente, C. Gonzalez-Herrada, and J. Jimenez-Reyes Treatment of toxic epidermal necrolysis with cyclosporin A J Trauma 48 2000 473 478
80. M. Fischer, E. Fiedler, W.C. Marsch, and J. Wohlrab Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis Br J Dermatol 146 2002 707 709
81. N.G. Frangogiannis, I. Boridy, M. Mazhar, R. Mathews, S. Gangopadhyay, and T. Cate Cyclophosphamide in the treatment of toxic epidermal necrolysis South Med J 89 1996 1001 1003
82. P. Wolkenstein, J. Latarjet, J.C. Roujeau, C. Duguet, S. Boudeau, and L. Vaillant Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis Lancet 352 1998 1586 1589
83. P. Redondo, I. de Felipe, A. de la Pena, J.M. Aramendia, and V. Vanaclocha Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine Br J Dermatol 136 1997 645 646
84. A. Velez, and J.C. Moreno Toxic epidermal necrolysis treated with N-acetylcysteine J Am Acad Dermatol 46 2002 469 470